Basilea Pharmaceutica AG (LON:0QNA)

Basilea Pharmaceutica AG Statistics

Total Valuation

LON:0QNA has a market cap or net worth of GBP 561.13 million. The enterprise value is 531.43 million.

Market Cap	561.13M
Enterprise Value	531.43M

Important Dates

The next estimated earnings date is Tuesday, February 17, 2026.

Earnings Date	Feb 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	12.29M
Shares Outstanding	n/a
Shares Change (YoY)	+15.14%
Shares Change (QoQ)	-0.29%
Owned by Insiders (%)	0.27%
Owned by Institutions (%)	33.45%
Float	12.25M

Valuation Ratios

The trailing PE ratio is 8.41 and the forward PE ratio is 13.04.

PE Ratio	8.41
Forward PE	13.04
PS Ratio	2.59
PB Ratio	5.93
P/TBV Ratio	5.95
P/FCF Ratio	7.84
P/OCF Ratio	7.69
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.05, with an EV/FCF ratio of 7.43.

EV / Earnings	7.97
EV / Sales	2.39
EV / EBITDA	7.05
EV / EBIT	7.38
EV / FCF	7.43

Financial Position

The company has a current ratio of 6.32, with a Debt / Equity ratio of 0.94.

Current Ratio	6.32
Quick Ratio	5.40
Debt / Equity	0.94
Debt / EBITDA	1.21
Debt / FCF	1.24
Interest Coverage	20.43

Financial Efficiency

Return on equity (ROE) is 121.16% and return on invested capital (ROIC) is 29.07%.

Return on Equity (ROE)	121.16%
Return on Assets (ROA)	21.88%
Return on Invested Capital (ROIC)	29.07%
Return on Capital Employed (ROCE)	35.70%
Revenue Per Employee	1.20M
Profits Per Employee	370,471
Employee Count	164
Asset Turnover	1.08
Inventory Turnover	4.69

Taxes

Income Tax	-346,925
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.99% in the last 52 weeks. The beta is 0.62, so LON:0QNA's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+7.99%
50-Day Moving Average	47.64
200-Day Moving Average	46.43
Relative Strength Index (RSI)	51.71
Average Volume (20 Days)	13,516

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LON:0QNA had revenue of GBP 216.79 million and earned 66.68 million in profits. Earnings per share was 5.02.

Revenue	216.79M
Gross Profit	100.57M
Operating Income	70.27M
Pretax Income	66.34M
Net Income	66.68M
EBITDA	71.66M
EBIT	70.27M
Earnings Per Share (EPS)	5.02

Balance Sheet

The company has 117.81 million in cash and 88.83 million in debt, giving a net cash position of 28.98 million.

Cash & Cash Equivalents	117.81M
Total Debt	88.83M
Net Cash	28.98M
Net Cash Per Share	n/a
Equity (Book Value)	94.68M
Book Value Per Share	7.71
Working Capital	168.02M

Cash Flow

In the last 12 months, operating cash flow was 72.96 million and capital expenditures -1.44 million, giving a free cash flow of 71.53 million.

Operating Cash Flow	72.96M
Capital Expenditures	-1.44M
Free Cash Flow	71.53M
FCF Per Share	n/a

Margins

Gross margin is 46.39%, with operating and profit margins of 32.41% and 30.76%.

Gross Margin	46.39%
Operating Margin	32.41%
Pretax Margin	30.60%
Profit Margin	30.76%
EBITDA Margin	33.05%
EBIT Margin	32.41%
FCF Margin	32.99%

Dividends & Yields

LON:0QNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.14%
Shareholder Yield	-15.14%
Earnings Yield	11.88%
FCF Yield	12.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0QNA has an Altman Z-Score of -0.09 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.09
Piotroski F-Score	8